Back to Top

Aims & Scope

Genetic Engineering & Biotechnology News (GEN) was the first publication in the field and remains the key driver in the explosion of the industry, paving the way for the development of new technologies and applications, investment growth, and career opportunities. Celebrating its 40th anniversary in 2021, GEN maintains unparalleled integrity, influence, and expertise that plays a pivotal role in driving the productivity and growth of the industry.

GEN’s breadth of editorial coverage is unrivaled in the industry, providing exclusive coverage across the entire spectrum of biotechnology in five core areas - Drug Discovery, Bioprocessing, OMICS, Translational Medicine, and Genome Editing - and now with expanded coverage in the emerging areas of Cancer Research, Infectious Diseases, and Artificial Intelligence/Big Data. The exclusive features, reporting, and analysis in GEN enable new scientific discoveries, accelerate the pace of research, and drive large-scale funding and investments.


  • Biotechnology Citation Index®
The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.